reltecimod

Peptideexperimental

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Sep 1, 2010 (NCT01166984)

Timeline

2010s

Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Jan 1, 2015
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

T-cell-specific surface glycoprotein CD28INHIBITOR
CD28 inhibitor
- T-cell-specific surface glycoprotein CD28 (CD28) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](C)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)O)C(C)C

Mol. weight: 1037.2 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL3989950 ↗

Also known as

ab103
ab103

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03403751	Phase 2	May 24, 2018	Atox Bio Ltd, University of Florida
NCT02469857	Phase 3	Sep 1, 2015	Atox Bio Ltd, Department of Health and Human Services, Harborview Injury Prevention and Research Center
NCT01417780	Phase 2	Dec 1, 2011	Atox Bio Ltd
NCT01166984	Phase 1	Sep 1, 2010	Atox Bio Ltd, University of Maryland

Showing 4 of 4 trials

Page 1 / 1

Organizations

Research & Development (5)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Atox Bio Ltd	For profit	4	4	3	2010
Department of Health and Human Services	Government	1	0	1	2015
Harborview Injury Prevention and Research Center	Academic/Hospital	1	0	1	2015
University of Florida	Academic/Hospital	1	0	1	2018
University of Maryland	Academic/Hospital	1	0	1	2010

5 organizations

Page 1 / 1